INTRODUCTION
Parkinson's disease (PD) is one of the most common neurodegenerative disorders that results from loss of neurons in the nigrostriatal pathway, which reduces dopamine levels in the striatum.
(1) Depletion of dopaminergic neurons are associated with the frontostriatal circuit, which modulates cognitive, motor and affective processes. (2) Specifically, this circuit is involved in executive functions required to initiate goal-directed behaviour and conflict resolution. (3) Cortical areas in the frontal lobe, including the dorsolateral prefrontal cortex and orbitofrontal cortices, are involved in information processing, rule-based learning, working memory, attention and planning. (4) Frontal cortical regions provide top-down regulation of attention, inhibition and cognitive control through connections with the posterior subcortical structures. These structures are sensitive to changes in the levels of neurotransmitters. Thus, brain functions get altered, but this can be improved by medication. (5) Decreased levels of dopamine in the brain can cause tremors, muscle rigidity and impaired reflexes. (6) These symptoms can be well controlled by levodopa (L-dopa), which is a standard treatment for PD.
PD is associated with decline across several cognitive functions, such as attention, memory and task switching, due to striatal dopaminergic depletion and global brain volume. (8, 9) The dopamine system is involved in cognitive decline associated with PD. This has been observed in the form of reduced 18 fluorodopa uptake in the frontal cortex and caudate nucleus in patients with PD during the performance of neuropsychological tests. (10) It has been observed that three-month L-dopa treatment for patients with PD has beneficial effects on their neuropsychological performance. (11) There is an increase in dopaminergic burst and excitatory activity in the direct pathway and inhibition of activity in the indirect pathway of the corticostriatal-thalamo-cortical loop with L-dopa medication. (12) As a result, irrelevant responses are suppressed and cognitive functions are improved. (13) (14) (15) In this study, we aimed to: 
RESULTS
The overall demographic and clinical characteristics of participants are shown in Table I failed to reach levels of significance.
DISCUSSION
In our study, patients with PD showed impaired performance, in contrast with the control group, on frontal-subcortical and posterior cortical cognitive functions at the time of diagnosis when patients were not taking any medication. PD is associated with decline across several cognitive functions, such as attention, memory and task-switching, due to striatal dopaminergic depletion and global brain volume. (8, 9) Cognitive deficits observed in patients with PD are similar to those associated with lesions of the prefrontal cortex. Circuits of the frontal cortex and basal ganglia are dependent upon levels of dopamine. Change in dopamine stimulation alters performance of the frontal cognitive functions. (21) Our results demonstrated that both frontal-subcortical and posterior cognitive functions were affected by dopaminergic depletion.
Among patients with PD, improvements were seen for several cognitive functions pertaining to frontal-subcortical functioning after L-dopa treatment. These cognitive functions included immediate free recall verbal memory, sustained attention, working memory, unprompted drawing of a clock, delayed free recall verbal memory, alternating verbal fluency and action verbal fluency. Likewise, L-dopa treatment improved performance on posterior cortical functioning in our study, as assessed through confrontation naming. Longitudinal studies have shown that dopamine transmission is critical for frontal cortical functions and the administration of L-dopa leads to improvements in cognitive dysfunctions in PD. (22) Previous studies have found that the corticostriatal circuits connecting both frontal and posterior regions to the dorsal caudate nucleus are dopamine depleted in PD and dopaminergic medication improves performance on cognitive tasks underlying these circuits. (23) Duration of disease was also found to be a significant predictor of the performance of frontal-subcortical and posterior cortical cognitive functions for patients with PD. This result was consistent with the findings of previous studies that have found that neuropsychological performance of patients with PD deteriorates as disease duration increases. (24, 25) To the best of our knowledge, this is the first study examining the effect of L-dopa on frontal-subcortical and posterior cortical cognitive functions as well as the various predictors of cognitive performance among patients with PD. Our findings would support clinical practice by helping in the early identification and treatment of cognitive decline in patients with PD.
We conclude that three-month L-dopa medication for patients with PD has beneficial effects for their frontal-subcortical and posterior cortical functions. Future studies should examine follow-up data of patients with PD to ascertain whether improvements seen in their frontal-subcortical and posterior cortical functions after L-dopa treatment is maintained several years after patients are taken off the medication.
